Clinical Chemistry and Laboratory Medicine (CCLM) · 2012 · 22 citations · 18 references
MedicineCardiologyClinical CardiologyClinical EpidemiologyPreventive CardiologyCardiac BiomarkersCardiac Risk AssessmentCardiovascular AssessmentCardiovascular DiseaseCardiovascular EpidemiologyPeptide AnalysisCardiac Biomarker EvaluationCardiovascular Disease PrevalenceCardiovascular Risk MarkersCardiovascular Risk StratificationStratification
BACKGROUND: The use of biomarkers is firmly established for the assessment of cardiovascular disease. Emerging biomarkers such as midregional pro-atrial natriuretic peptide (MR-proANP) challenge established markers regarding risk prediction and stratification ability. The aim of the present study was to describe the distribution of a contemporary MR-proANP assay in a large population-representative sample and to evaluate the association with prevalent cardiac diseases and cardiovascular risk factors. METHODS: MR-proANP was determined by the use of a contemporary commercially available assay (BRAHMS GmbH, Hennigsdorf, Germany) in a representative sample of 5000 participants from the large population-based Gutenberg Health Study. N-terminal pro B-type natriuretic peptide (NT-proBNP) was used as a comparator. RESULTS: Mean age was 55.5 ± 10.9 years. Coronary artery disease (CAD) was documented in 4.6%, heart failure (HF) in 1.5% of the study participants. We observed a moderate to strong correlation of the biomarkers with age, diabetes, hypertension, smoking, renal function, prevalence of CAD and HF. Males showed lower MR-proANP concentrations than females. MR-proANP showed no relevant correlation with BMI (ρ=-0.030) and CRP (ρ=0.039). Reference limits for MR-proANP representing the 95th/97.5th/99th percentile were determined for healthy individuals with 116/132/169 pmol/mL. CONCLUSIONS: The current analysis in a large population-based sample elucidates the correlations and distribution of MR-proANP. Its concentration in healthy individuals depends on prevalent cardiovascular diseases and classical risk factors. The reported population-based reference values might be useful for distinguishing between healthy and diseased individuals, thus improving risk stratification and triaging in various clinical settings.
18
John J.V. McMurray, Stamatis Adamopoulos, Stefan D. Anker et al. · European Heart Journal · 2012 · 6.9K citations · Full text
K. Thygesen, Joseph S. Alpert, Harvey D. White et al. · European Heart Journal · 2007 · 2.5K citations · Full text
Andrew S. Levey, Josef Coresh, Tom Greene et al. · Clinical Chemistry · 2007 · 1.9K citations · Full text
Plasma Natriuretic Peptide Levels and the Risk of Cardiovascular Events and Death
Thomas J. Wang, Martin G. Larson, Daniel Levy et al. · New England Journal of Medicine · 2004 · 1.5K citations · Full text
Medicine, Cardiology, Physiology +11